Bora Lim, M.D.

Peer-Reviewed Articles

1. Chen, J, Balema, W, Krishnamurthy, S, Lawrence, AN, Fowlkes, NW, Larson, R, Shivhare, S, Sanchez, CI, Rodriguez, MM, Lee, J, Schlee Villodre, E, Debeb, BG, Ueno, NT, Van Laere, SJ, Bertucci, F, Cho, H, Sulman, EP, Lim, B, Woodward, W. CCR7 immune cell receptor expression in inflammatory breast cancer. Scientific reports 16(1), 2026. e-Pub 2026. PMID: 41832292.
2. Yan Y, Lin Y, Kumar T, Bai S, Thennavan A, Li J, Sei E, Tran T, Hu M, Rao M, Tang C, He S, Casasent A, Ravenberg E, Rauch GM, Clayborn AR, Tripathy D, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Ecotypes of triple-negative breast cancer in response to chemotherapy. Nature 654(8120):1088-1097, 2026. e-Pub 2026. PMID: 42129561.
3. Sukumar, J, Niu, J, Jackson, I, Singareeka Raghavendra, A, Lim, B, Basen-Engquist, KM, Giordano, SH. Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients. Journal of Clinical Oncology 44:629, 2026. e-Pub 2026.
4. Lopez, ER, Alexander, A, Marx, AN, Li, X, Knafl, M, Woodman, SE, Cao, J, Liu, S, Darbonne, WC, Woodward, W, Valero, V, Lim, B. Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states. Journal of Clinical Oncology 44, 2026. e-Pub 2026.
5. Singareeka Raghavendra, A, Tarasov, A, Mouabbi, JA, Evdokimova, A, Smirnov, V, Rumyantsev, K, Barcenas, CH, Layman, RM, Savin, E, Lim, B, Pohlmann, PR, Damodaran, S, Hensley, M, Makani, N, Ogloblina, A, Fowler, N, Giordano, SH, Bagaev, A, Yam, C, Tripathy, D. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). Journal of Clinical Oncology 44:e13080-e13080, 2026. e-Pub 2026.
6. Dai, Y, Pan, X, Guo, S, Ji, S, Cao, S, Montierth, M, Jiang, Y, Chang, J, Shi, LM, Shalapour, S, Echeverria, GV, Yates, LR, Staaf, J, Lim, B, Yuan, Y, Wang, W. Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer. Cell Reports Medicine 7(2), 2026. e-Pub 2026. PMID: 41707645.
7. Wang J, Minussi DC, Davis A, Wei R, Ye H, Sei E, Schalck A, Yan Y, Wu HJ, Bai S, Peng C, Hu M, Casasent A, Contreras A, Chen H, Hui D, Damodaran S, Edgerton ME, Kopetz S, Lim B, Navin N. Delineating the copy-number substructure of metastatic tumors with CopyKit. Mol Cell 86(2):407-422.e6, 2026. e-Pub 2026. PMID: 41534520.
8. Nasrazadani A, Tidwell RS, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Debeb BG, Lucci A, Woodward WA, Layman RM. Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition. Breast Cancer Res 28(1):8, 2025. e-Pub 2025. PMID: 41372771.
9. Azhar, M, Soto, F, Su, A, Gonzalez, NV, Medina, KB, Madrigal, AL, Duran, CC, Reyna, CR, Chan, C, Shroff, G, Bassett Jr, R, Pasyar, S, Zhang, D, Shannon, VR, Altan, M, Mitchell, MP, Meric-Bernstam, F, Mouabbi, JA, Murthy, RK, Faiz, S, Bashoura, L, Lim, B, Sheshadri, A. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 41194091.
10. Wang R, Luo M, Liu Y, Yang J, Chen Y, Chen C, Ma L, Ding S, Wengler J, Zang Y, Lim B, Li W, Yang L, Lin C, Diao L, Han L. Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer. Adv Sci (Weinh) 13(6):e13414, 2025. e-Pub 2025. PMID: 41270088.
11. Lim, B, Marx, AN, Kai, M, Alexander, A, Bassett Jr, R, Ma, W, Willey, J, Sun, H, Nasrazadani, A, Mohammad, MM, Zhang, J, Lucci, A, Sun, SX, Stauder, MC, Whitman, GJ, Le-Petross, H, Valero, V, Woodward, W, Layman, RM. A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease). Therapeutic Advances in Medical Oncology 17, 2025. e-Pub 2025. PMID: 41116969.
12. Zheng ZY, Chen A, Jaehnig EJ, Anurag M, Lei JT, Feng L, Wang C, Fandino D, Singh P, Kennedy H, Yadav G, Vollert CT, Tsai J, Chen X, Li Y, Lim B, Thompson A, Li S, Foulds CE, Zhang B, Ellis MJ, Chang EC. NF1-depleted ER(+) breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med 17(813):eadq5492, 2025. e-Pub 2025. PMID: 40864686.
13. Zhao Z, Hu B, Deng Y, Soeung M, Yao J, Bei L, Zhang Y, Gong P, Huang LA, Jiang Z, Gao J, Peng S, Nguyen TK, Karki M, Lim B, Yee C, Burks JK, Zhang Q, Ma L, Gao J, Tannir NM, Han L, Yu D, Wang L, Curran MA, Gubbiotti MA, Genovese G, Gan B, Li W, Msaouel P, Yang L, Lin C. Sickle cell disease induces chromatin introversion and ferroptosis in CD8(+) T cells to suppress anti-tumor immunity. Immunity 58(6):1484-1501.e11, 2025. e-Pub 2025. PMID: 40359940.
14. Kouzy, R, Kai, M, Le-Petross, HT, Saleem, S, Layman, RM, Lim, B, Nasrazadani, A, Saleem, S, Valero, V, Stauder, MC, Lucci, A, Sun, SX, Whitman, GJ, Patel, MM, Le-Petross, H, Lu, Y, Marx, AN, Alexander, A, Yajima, C, Kai, M, Villareal, L, Lopez, H, Woodward, W. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system. JNCI Cancer Spectrum 9(3), 2025. e-Pub 2025. PMID: 40493814.
15. Kinloch AJ, Rahman F, Karakas B, Shahid M, Lim B, Bouley SJ, Walker JA, Lee EF, Fairlie WD, Kelly KR, Cardone MH. Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs. Cancers (Basel) 17(11), 2025. e-Pub 2025. PMID: 40507334.
16. Mughees M, Tacam MJ, Tan AW, Pitner MK, Iles LR, Hu X, S Villodre E, Debeb BG, Kogawa T, Lim B, Layman RM, Woodward WA, Ueno NT, Tripathy D, Krishnamurthy S, Qi Y, Pusztai L, Wang J, Gandhi V, Bartholomeusz G, Bartholomeusz C. Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers. Mol Cancer Ther 24(9):1453-1465, 2025. e-Pub 2025. PMID: 40358476.
17. Alam R, Reva A, Edwards DG, Lege BM, Munoz-Arcos LS, Reduzzi C, Singh S, Hao X, Wu YH, Tian Z, Natalee LM, Damle G, Demircioglu D, Wang Y, Wu L, Molteni E, Hasson D, Lim B, Gugala Z, Chipuk JE, Lang JE, Sparano JA, Cheng C, Cristofanilli M, Xiao H, Zhang XH, Bado IL. Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov 15(4):818-837, 2025. e-Pub 2025. PMID: 39835789.
18. Kontoyiannis, PD, Kuykendal, A, Tang, C, Cheng, JP, Chan, B, Thomas, SS, Rao, P, Lim, B, Msaouel, P. Case Report. Frontiers in Oncology 15, 2025. e-Pub 2025. PMID: 40951353.
19. Lin, Y, Wang, J, Wang, K, Bai, S, Thennavan, A, Wei, R, Yan, Y, Li, J, Elgamal, H, Sei, E, Casasent, A, Rao, M, Tang, C, Multani, AS, Ma, J, Montalvan, J, Nagi, C, Winocour, SJ, Lim, B, Thompson, A, Navin, NE. Normal breast tissues harbour rare populations of aneuploid epithelial cells. Nature 636(8043):663-670, 2024. e-Pub 2024. PMID: 39567687.
20. Morita D, Rosewell Shaw A, Biegert G, Porter C, Woods M, Vasileiou S, Lim B, Suzuki M. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer 12(12), 2024. e-Pub 2024. PMID: 39653552.
21. Huang ML, Lane DL, Chang Sen LQ, Candelaria RP, Kuerer HM, Hunt KK, Akay C, Lim B, Shaitelman S, Hwang RF, Chen H, Katta R, Santiago L. Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer. Acad Radiol 31(12):4759-4771, 2024. e-Pub 2024. PMID: 39107186.
22. Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
23. Hao X, Shen Y, Liu J, Alexander A, Wu L, Xu Z, Yu L, Gao Y, Liu F, Chan HL, Li CH, Ding Y, Zhang W, Edwards DG, Chen N, Nasrazadani A, Ueno NT, Lim B, Zhang XH. Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions. Nat Cell Biol 26(11):1971-1983, 2024. e-Pub 2024. PMID: 39266726.
24. Lim, B, Seth, S, Yam, C, Huo, L, Fujii, T, Lee, J, Bassett Jr, R, Nasser, S, Ravenberg, L, White, JB, Clayborn, A, Guerra, G, Litton, J, Damodaran, S, Layman, RM, Valero, V, Tripathy, D, Lewis, MT, Dobrolecki, LE, Lei, JT, Candelaria, RP, Arun, BK, Rauch, GM, Zhao, L, Zhang, J, Ding, Q, Symmans, WF, Chang, J, Thompson, A, Moulder, S, Ueno, NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
25. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res 30(11):2424-2432, 2024. e-Pub 2024. PMID: 38629963.
26. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
27. Zhang, Y, Zhao, Z, Huang, L, Liu, Y, Yao, J, Sun, C, Li, Y, Zhang, Z, Ye, Y, Yuan, F, Nguyen, TK, Garlapati, NR, Wu, A, Egranov, SD, Caudle, AS, Sahin, AA, Lim, B, Beretta, L, Calin, GA, Yu, D, Hung, MC, Curran, M, Rezvani, K, Gan, B, Tan, Z, Han, L, Lin, C, Yang, L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metabolism 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
28. Kumar, T, Nee, K, Wei, R, He, S, Nguyen, QH, Bai, S, Blake, K, Pein, M, Gong, Y, Sei, E, Hu, M, Casasent, A, Thennavan, A, Li, J, Tran, TM, Chen, K, Nilges, B, Kashikar, N, Braubach, O, Ben Cheikh, B, Nikulina, N, Chen, H, Teshome, M, Menegaz, BA, Javaid, H, Nagi, C, Montalvan, J, Lev, T, Mallya, S, Tifrea, DF, Edwards, RA, Lin, E, Parajuli, R, Hanson, SE, Winocour, SJ, Thompson, A, Lim, B, Lawson, DA, Kessenbrock, K, Navin, N. A spatially resolved single-cell genomic atlas of the adult human breast. Nature 620(7972):181-191, 2023. e-Pub 2023. PMID: 37380767.
29. Kim, BJ, Zheng, ZY, Lei, JT, Holt, MV, Chen, A, Peng, J, Fandino, D, Singh, P, Kennedy, H, Dou, Y, del Rosario Chica-Parrado, M, Bikorimana, E, Ye, D, Wang, Y, Hanker, AB, Mohamed, N, Hilsenbeck, SG, Lim, B, Asirvatham, JR, Sreekumar, A, Zhang, B, Miles, G, Anurag, M, Ellis, MJ, Chang, EC. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment. Cancer Research Communications 3(7):1366-1377, 2023. e-Pub 2023. PMID: 37501682.
30. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
31. Oropeza, E, Seker, S, Carrel, S, Mazumder, A, Lozano, D, Jimenez, A, VandenHeuvel, SN, Noltensmeyer, DA, Punturi, N, Lei, JT, Lim, B, Waltz, SE, Raghavan, S, Bainbridge, M, Haricharan, S. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Science Advances 9(26), 2023. e-Pub 2023. PMID: 37390209.
32. Abuhadra N, Sun R, Bassett RL Jr, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
33. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
34. Hao, X, Shen, Y, Chen, N, Zhang, W, Valverde, E, Wu, L, Chan, HL, Xu, Z, Yu, L, Gao, Y, Bado, I, Michie, LN, Rivas, C, Dominguez, LB, Aguirre, S, Pingel, BC, Wu, YH, Liu, F, Ding, Y, Edwards, DE, Liu, J, Alexander, A, Ueno, NT, Hsueh, PR, Tu, C, Liu, L, Chen, SH, Hung, MC, Lim, B, Zhang, XH. Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell 30(5):648-664.e8, 2023. e-Pub 2023. PMID: 37146584.
35. Lee KH, Lee SY, Lim B, Park K. A Case of Solitary Fibrous Tumor on the Foot. Ann Dermatol 35(Suppl 1):S176-S177, 2023. e-Pub 2023. PMID: 37853904.
36. Kumar T, Nee K, Wei R, He S, Nguyen QH, Bai S, Blake K, Gong Y, Pein M, Sei E, Hu M, Casasent A, Thennavan A, Li J, Tran T, Chen K, Nilges B, Kashikar N, Braubach O, Cheikh BB, Nikulina N, Chen H, Teshome M, Menegaz B, Javaid H, Nagi C, Montalvan J, Tifrea DF, Edwards R, Lin E, Parajuli R, Winocour S, Thompson A, Lim B, Lawson DA, Kessenbrock K, Navin N. A spatially resolved single cell genomic atlas of the adult human breast. bioRxiv, 2023. e-Pub 2023. PMID: 37163043.
37. Wang, DY, Porter, CE, Lim, B, Shaw, AR, Robertson, C, Woods, ML, Xu, Y, Grossman Biegert, GW, Morita, D, Wang, T, Grilley, B, Heslop, H, Brenner, MK, Suzuki, M. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advances 9(13), 2023. e-Pub 2023. PMID: 36989357.
38. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Kai M, Song J, Shen Y, Willey JS, Lim B, Valero V, Ueno NT, Reuben JM. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900406.
39. Baek ML, Lee J, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Mahmud I, Wang T, Meyer MD, Lim B, Barrish JP, Porter W, Lorenzi PL, Echeverria GV. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment. Oncogene 42(14):1117-1131, 2023. e-Pub 2023. PMID: 36813854.
40. Chen, H, Ding, Q, Khazai, L, Zhao, L, Damodaran, S, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Virani, K, White, JB, Ravenberg, EE, Song, X, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Routbort, MJ, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Wang, WL, Moulder, S, Huo, L. PTEN in triple-negative breast carcinoma. Therapeutic Advances in Medical Oncology 15, 2023. e-Pub 2023. PMID: 37547448.
41. Lee H, Jung S, Gong G, Lim B, Lee HJ. Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer. PLoS One 18(8):e0289627, 2023. e-Pub 2023. PMID: 37540709.
42. Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, J, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Glitza, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature communications 13(1), 2022. e-Pub 2022. PMID: 35413951.
43. Stires, H, Bado, I, Brown, T, Carlson, M, Chan, IS, Echeverria, GV, Ewald, AJ, Lim, B, Lloyd, C, Maues, J, Oesterreich, S, Riter, RN, Shanahan, K, Welm, AL, Newby, J. Improving the odds together. npj Breast Cancer 8(1), 2022. e-Pub 2022. PMID: 35773258.
44. Zhang, Y, Sun, C, Li, Y, Qin, J, Amancherla, K, Jing, Y, Hu, Q, Liang, K, Zhang, Z, Ye, Y, Huang, L, Nguyen, TK, Egranov, SD, Zhao, Z, Wu, A, Xi, Y, Yao, J, Hung, MC, Calin, GA, Cheng, J, Lim, B, Lehmann, LH, Salem, JE, Johnson, DB, Curran, M, Yu, D, Han, L, Darabi, R, Yang, L, Moslehi, JJ, Lin, C. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Science translational medicine 14(669), 2022. e-Pub 2022. PMID: 36322628.
45. Cao, S, Wang, RJ, Ji, S, Yang, P, Dai, Y, Guo, S, Montierth, MD, Shen, JY, Zhao, X, Chen, J, Lee, JJ, Guerrero, PA, Spetsieris, N, Engedal, N, Taavitsainen, S, Yu, K, Livingstone, J, Bhandari, V, Hubert, SM, Daw Bitar, N, Futreal, A, Efstathiou, E, Lim, B, Viale, A, Zhang, J, Nykter, M, Czerniak, BA, Brown, PH, Swanton, C, Msaouel, P, Maitra, A, Kopetz, S, Campbell, PJ, Speed, TP, Boutros, PC, Zhu, H, Urbanucci, A, Demeulemeester, J, Van Loo, P, Wang, W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
46. Lee, J, Thall, PF, Lim, B, Msaouel, P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. Journal of the Royal Statistical Society. Series C: Applied Statistics 71(5):1605-1622, 2022. e-Pub 2022. PMID: 36714159.
47. Anurag, M, Jaehnig, EJ, Krug, K, Lei, JT, Bergstrom, EJ, Kim, BJ, Vashist, TD, Huynh, AT, Dou, Y, Gou, X, Huang, C, Shi, Z, Wen, B, Korchina, V, Gibbs, RA, Muzny, DM, Doddapaneni, HV, Dobrolecki, LE, Rodriguez, H, Robles, AI, Hiltke, T, Lewis, MT, Nangia, JR, Shafaee, MN, Li, S, Hagemann, IS, Hoog, J, Lim, B, Osborne, CK, Mani, DR, Gillette, MA, Zhang, B, Echeverria, GV, Miles, G, Rimawi, MF, Carr, SA, Ademuyiwa, F, Satpathy, S, Ellis, MJ. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer discovery 12(11):2586-2605, 2022. e-Pub 2022. PMID: 36001024.
48. Yan, G, Luna, A, Wang, H, Bozorgui, B, Li, X, Sanchez, M, Dereli Korkut, Z, Kahraman, N, Kara, G, Chen, X, Zheng, C, McGrail, DJ, Sahni, N, Lu, Y, Babur, Ö, Cokol, M, Lim, B, Ozpolat, B, Sander, C, Mills, GB, Korkut, A. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Reports 40(11), 2022. e-Pub 2022. PMID: 36103824.
49. Kalra, R, Chen, CH, Wang, J, Salam, AB, Dobrolecki, LE, Lewis, A, Sallas, C, Yates, C, Gutierrez, C, Karanam, B, Anurag, M, Lim, B, Ellis, MJ, Kavuri, SM. Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Research 82(16):2928-2939, 2022. e-Pub 2022. PMID: 35736563.
50. Irajizad, E, Wu, R, Vykoukal, JV, Murage, EN, Spencer, R, Dennison, JB, Moulder, S, Ravenberg, EE, Lim, B, Litton, J, Tripathym, D, Valero, V, Damodaran, S, Rauch, GM, Adrada, BE, Candelaria, RP, White, JB, Brewster, A, Arun, BK, Long, JP, Do, K, Hanash, S, Fahrmann, JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Frontiers in Artificial Intelligence 5, 2022. e-Pub 2022. PMID: 36034598.
51. Yam, C, Abuhadra, NK, Sun, R, Adrada, BE, Ding, Q, White, JB, Ravenberg, EE, Clayborn, A, Valero, V, Tripathy, D, Damodaran, S, Arun, BK, Litton, J, Ueno, NT, Murthy, RK, Lim, B, Báez, L, Li, X, Buzdar, AU, Hortobagyi, GN, Thompson, A, Mittendorf, EA, Rauch, GM, Candelaria, RP, Huo, L, Moulder, S, Chang, JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
52. Haque, W, Verma, V, Schwartz, MR, Lim, B, Mangalampalli, N, Butler, EB, Teh, BS. Neoadjuvant Chemotherapy for Metaplastic Breast Cancer. Clinical breast cancer 22(5):e691-e699, 2022. e-Pub 2022. PMID: 35193807.
53. Kalra, M, Henry, E, McCann, K, Karuturi, MS, Bustamante Alvarez, JG, Parkes, A, Wesolowski, R, Wei, M, Mougalian, SS, Durm, GA, Qin, A, Schonewolf, CA, Trivedi, M, Armaghani, A, Wilson, FH, Iams, WT, Turk, AA, Vikas, P, Cecchini, M, Lubner, SJ, Pathak, P, Spencer, K, Koshkin, VS, Labriola, MK, Marshall, CH, Beckermann, KE, Sharifi, MN, Bejjani, AC, Hotchandani, V, Housri, S, Housri, N, Soliman, H, Tripathy, D, Hershman, D, Otterson, GA, Ramaswamy, B, Carbone, DP, Jalal, SI, Hanna, N, Kalinsky, K, Tevaarwerk, AJ, Barcenas, CH, Wisinski, KB, Lustberg, MB, Horn, L, Crew, KD, Owen, D, Lim, B, Arun, BK, Ueno, NT. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board. JMIR Cancer 8(2), 2022. e-Pub 2022. PMID: 35588361.
54. Abuhadra, NK, Sun, R, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Bassett Jr, R, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, White, JB, Ravenberg, EE, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Moulder, S, Huo, L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers 14(5), 2022. e-Pub 2022. PMID: 35267631.
55. Masuda, H, Harano, K, Miura, S, Wang, Y, Hirota, Y, Harada, O, Jolly, MK, Matsunaga, Y, Lim, B, Wood, AL, Parinyanitikul, N, Lee, HJ, Gong, G, George, JT, Levine, H, Lee, J, Wang, X, Lucci, A, Uppore Kukkillaya, AR, Schweitzer, BL, Lawrence, OR, Seitz, RS, Morris, SW, Hout, DR, Nakamura, S, Krishnamurthy, S, Ueno, NT. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology 6, 2022. e-Pub 2022. PMID: 35294223.
56. Postlewait, LM, Teshome, M, Adesoye, T, DeSnyder, SM, Lim, B, Kuerer, HM, Bedrosian, I, Sun, SX, Woodward, W, Le-Petross, H, Valero, V, Ueno, NT, Lucci, A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of surgical oncology 28(13):8610-8621, 2021. e-Pub 2021. PMID: 34125346.
57. Kai, M, Marx, AN, Liu, D, Shen, Y, Gao, H, Reuben, JM, Whitman, GJ, Krishnamurthy, S, Ross, MI, Litton, J, Lim, B, Ibrahim, NK, Kogawa, T, Ueno, NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Scientific reports 11(1), 2021. e-Pub 2021. PMID: 34782633.
58. Evans, KW, Yuca, E, Scott, S, Zhao, M, Arango, NP, Cruz Pico, CX, Saridogan, T, Shariati, M, Class, CA, Bristow, C, Vellano, CP, Zheng, X, González-Angulo, AM, Su, X, Tapia, C, Chen, K, Akcakanat, A, Lim, B, Tripathy, D, Yap, TA, Di Francesco, ME, Draetta, G, Jones, PH, Heffernan, TP, Marszalek, JR, Meric-Bernstam, F. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer. Cancer Research 81(21):5572-5581, 2021. e-Pub 2021. PMID: 34518211.
59. Huang, X, Chen, H, Ding, Q, Robinson, M, Moseley, T, Bassett Jr, R, Tang, G, Lim, B, Sahin, AA. Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma. Human Pathology 117:51-59, 2021. e-Pub 2021. PMID: 34363799.
60. Wang, K, Xiao, Z, Yan, Y, Ye, R, Hu, M, Bai, S, Sei, E, Qiao, Y, Chen, H, Lim, B, Lin, SH, Navin, N. Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility. Molecular cell 81(20):4319-4332.e10, 2021. e-Pub 2021. PMID: 34686316.
61. Yam, C, Yen, EY, Chang, JT, Bassett Jr, R, Al-Atrash, G, Garber, HR, Huo, L, Yang, F, Philips, A, Ding, Q, Lim, B, Ueno, NT, Kannan, KS, Sun, X, Sun, B, Parra Cuentas, ER, Symmans, WF, White, JB, Ravenberg, EE, Seth, S, Guerriero, JL, Rauch, GM, Damodaran, S, Litton, J, Wargo, J, Hortobagyi, GN, Futreal, A, Wistuba, II, Sun, R, Moulder, S, Mittendorf, EA. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clinical Cancer Research 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
62. Lim, B, Peterson, CB, Davis, A, Cho, E, Pearson, T, Liu, H, Hwang, MH, Ueno, NT, Lee, J. ONC201 and an MEK inhibitor trametinib synergistically inhibit the growth of triple-negative breast cancer cells. Biomedicines 9(10), 2021. e-Pub 2021. PMID: 34680527.
63. Partain, NS, Postlewait, LM, Teshome, M, Rosso, KJ, Hall, CS, Song, J, Meas, S, DeSnyder, SM, Lim, B, Valero, V, Woodward, W, Ueno, NT, Kuerer, HM, Lucci, A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of surgical oncology 28(8):4265-4274, 2021. e-Pub 2021. PMID: 33403525.
64. Lee, J, Liu, H, Pearson, T, Iwase, T, Fuson, JA, Lalani, AS, Eli, LD, Diala, I, Tripathy, D, Lim, B, Ueno, NT. Pi3k and mapk pathways as targets for combination with the pan-her irreversible inhibitor neratinib in her2-positive breast cancer and tnbc by kinome rnai screening. Biomedicines 9(7), 2021. e-Pub 2021. PMID: 34203351.
65. Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care 11(2):170-179, 2021. e-Pub 2020. PMID: 31924662.
66. Lim, B, Potter, DA, Salkeni, MA, Silverman, P, Haddad, T, Forget, F, Awada, A, Canon, J, Danso, MA, Lortholary, A, Bourgeois, H, Tan-Chiu, E, Vincent, S, Bahamon, B, Galinsky, KJ, Patel, CG, Neuwirth, R, Leonard, EJ, Diamond, JR. Sapanisertib plus exemestane or fulvestrant in women with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer. Clinical Cancer Research 27(12):3329-3338, 2021. e-Pub 2021. PMID: 33820779.
67. Cerna, D, Lim, B, Adelabu, Y, Yoo, S, Carter, D, Fahim, A, Mitsuuchi, Y, Teicher, BA, Bernhard, EJ, Coleman, CN, Takebe, N, Ahmed, MM. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme. Radiation research 195(6):549-560, 2021. e-Pub 2021. PMID: 33826739.
68. McGrail, DJ, Pilie, PG, Rashid, N, Voorwerk, L, Slagter, M, Kok, M, Jonasch, E, Khasraw, M, Heimberger, AB, Lim, B, Ueno, NT, Litton, J, Ferrarotto, R, Chang, JT, Moulder, S, Lin, S. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
69. Minussi, DC, Nicholson, MD, Ye, H, Davis, A, Wang, K, Baker, T, Tarabichi, M, Sei, E, Du, H, Rabbani, M, Peng, C, Hu, M, Bai, S, Lin, Yw, Schalck, A, Multani, AS, Ma, J, McDonald, TO, Casasent, A, Barrera, AG, Chen, H, Lim, B, Arun, BK, Meric-Bernstam, F, Van Loo, P, Michor, F, Navin, N. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-308, 2021. e-Pub 2021. PMID: 33762732.
70. Yam, C, Rauch, GM, Rahman, T, Karuturi, MS, Ravenberg, EE, White, JB, Clayborn, A, McCarthy, P, Abouharb, S, Lim, B, Litton, J, Ramirez, DL, Saleem, S, Stec, J, Symmans, WF, Huo, L, Damodaran, S, Sun, R, Moulder, S. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
71. Sun, H, Chen, H, Crespo, J, Tang, G, Robinson, M, Lim, B, Sahin, AA. Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy. European Journal of Breast Health 17(2):128-136, 2021. e-Pub 2021. PMID: 33870112.
72. Winer, A, Denlinger, CS, Vijayvergia, N, Cohen, SJ, Astaturov, I, Dotan, E, Gallant, JN, Wang, W, Kunkel, M, Lim, B, Harvey, H, Sivik, J, Korzekwa, K, Ruth, K, White, K, Cooper, HS, Ross, E, Zhou, L, El-Deiry, WS. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clinical colorectal cancer 20(1):e43-e52, 2021. e-Pub 2021. PMID: 32972830.
73. Chainitikun, S, Saleem, S, Lim, B, Valero, V, Ueno, NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research 29:1-12, 2021. e-Pub 2021. PMID: 33842000.
74. Lim, B, Song, J, Ibrahim, NK, Koenig, KB, Chavez Mac Gregor, M, Ensor, J, Gomez, JS, Krishnamurthy, S, Caudle, AS, Shaitelman, SF, Whitman, GJ, Valero, V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2021. PMID: 33140515.
75. Oh M, Laugeson E, Kim JH, Lee K, Kim J, Lee S, Lim B, Cha S, Bong G, Yoon NH, Bahn GH, Yoo HJ. A Randomized Controlled Trial of the Korean Version of the Program for the Education and Enrichment of Relational Skills for Young Adults (PEERS(R)-YA-K) With Autism Spectrum Disorder: A Pilot Study. Front Psychiatry 12:730448, 2021. e-Pub 2021. PMID: 34690837.
76. Kida, K, Hess, KR, Lim, B, Iwase, T, Chainitikun, S, Valero, V, Lucci, A, Le-Petross, H, Woodward, W, Krishnamurthy, S, Hortobagyi, GN, Tripathy, D, Ueno, NT. Validation of prognostic stage and anatomic stage in the American joint committee on cancer 8th edition for inflammatory breast cancer. Cancers 12(11):1-11, 2020. e-Pub 2020. PMID: 33114311.
77. Crespo, J, Sun, H, Wu, J, Ding, Q, Tang, G, Robinson, M, Chen, H, Sahin, AA, Lim, B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PloS one 15(11 November), 2020. e-Pub 2020. PMID: 33180796.
78. Li, P, Lu, M, Shi, J, Gong, Z, Hua, L, Li, Q, Lim, B, Zhang, XH, Chen, X, Li, S, Shultz, L, Ren, G. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nature Immunology 21(11):1444-1455, 2020. e-Pub 2020. PMID: 32958928.
79. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Ann Surg Oncol 27(12):4603-4612, 2020. e-Pub 2020. PMID: 32710271.
80. Milbury K, Weathers SP, Durrani S, Li Y, Whisenant M, Li J, Lim B, Weinberg JS, Kesler SR, Cohen L, Bruera E. Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled Trial. J Pain Symptom Manage 59(6):1260-1267, 2020. e-Pub 2020. PMID: 32061834.
81. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist 25(6):e909-e919, 2020. e-Pub 2020. PMID: 32003919.
82. Kim E, Yang SM, Lim B, Park SH, Rackerby B, Kim HY. Design of PCR assays to specifically detect and identify 37 Lactobacillus species in a single 96 well plate. BMC Microbiol 20(1):96, 2020. e-Pub 2020. PMID: 32295530.
83. Lim YJ, Lim B, Kim HY, Kwon SJ, Eom SH. Deglycosylation patterns of isoflavones in soybean extracts inoculated with two enzymatically different strains of lactobacillus species. Enzyme Microb Technol 132:109394, 2020. e-Pub 2020. PMID: 31731960.
84. Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS One 15(4):e0231953, 2020. e-Pub 2020. PMID: 32353087.
85. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9(3):1025-1032, 2019. e-Pub 2019. PMID: 31849202.
86. Ding, Q, Chen, H, Lim, B, Damodaran, S, Chen, W, Tripathy, D, Piha-Paul, SA, Luthra, R, Meric-Bernstam, F, Sahin, AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology 92:32-38, 2019. e-Pub 2019. PMID: 31351155.
87. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 176(1):251, 2019. e-Pub 2019. PMID: 30982934.
88. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 175(2):339-351, 2019. e-Pub 2019. PMID: 30826934.
89. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
90. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
91. Kang S, Kim EH, Hwang JE, Shin JH, Jeong YS, Yim SY, Joo EW, Eun YG, Lee DJ, Sohn BH, Lee SH, Lim B, Lee JS. Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. Biochem Biophys Res Commun 511(1):185-191, 2019. e-Pub 2019. PMID: 30777332.
92. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
93. Lim B, Matsuda N, Wang X, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol 4(9):1207-1213, 2018. e-Pub 2018. PMID: 29879283.
94. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat 171(2):501-511, 2018. e-Pub 2018. PMID: 29915946.
95. Kim HJ, Lee HJ, Lim B, Kim E, Kim HY, Suh M, Hur M. Lactobacillus terrae sp. nov., a novel species isolated from soil samples in the Republic of Korea. Int J Syst Evol Microbiol 68(9):2906-2911, 2018. e-Pub 2018. PMID: 30010525.
96. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
97. He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149(3):253-261, 2018. e-Pub 2018. PMID: 29425258.
98. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget 9(6):6872-6882, 2018. e-Pub 2018. PMID: 29467936.
99. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS One 13(10):e0204513, 2018. e-Pub 2018. PMID: 30312311.
100. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer 9(8):1437-1447, 2018. e-Pub 2018. PMID: 29721054.
101. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 28(10):2420-2428, 2017. e-Pub 2017. PMID: 28961844.
102. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno N. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol 3(9):1266-1273, 2017. e-Pub 2017. PMID: 28301631.
103. Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res 23(16):4780-4792, 2017. e-Pub 2017. PMID: 28465444.
104. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat 166(3):819-832, 2017. e-Pub 2017. PMID: 28831670.
105. Ralff MD, Kline CLB, Kucukkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther 16(7):1290-1298, 2017. e-Pub 2017. PMID: 28424227.
106. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad T. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 7(493-511):493-511, 2017. e-Pub 2017. PMID: 28717401.
107. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 163(2):263-272, 2017. e-Pub 2017. PMID: 28243898.
108. Sato N, Wakabayashi M, Nakatsuji M, Shimoji N, Sakamoto S, Ishida A, Lee J, Lim B, Ueno NT, Ishihara H, Inui T. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun 489(4):484-489, 2017. e-Pub 2017. PMID: 28576487.
109. Matsuda N, Lim B, Wang X, Ueno NT. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs 26(4):1-17, 2017. e-Pub 2017. PMID: 28271910.
110. Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One 12(9):e0185231, 2017. e-Pub 2017. PMID: 28957377.
111. Lim B, Hortobagyi GN. Current challenges of metastatic breast cancer. Cancer Metastasis Rev 35(4):495-514, 2016. e-Pub 2016. PMID: 27933405.
112. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. e-Pub 2016. PMID: 27602582.
113. Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget 7(4):3662-76, 2016. e-Pub 2016. PMID: 26695546.
114. Allen JE, Prabhu V, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-Inducing anticancer agent ONC201/TIC10. Cancer Res 75(8):1668-74, 2015. e-Pub 2015. PMID: 25681273.
115. Ma Y, Hao S, Wang S, Zhao Y, Lim B, Lei M, Spector DJ, El-Deiry WS, Zheng SY, Zhu J. A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Mol Cancer Ther 14(3):835-43, 2015. e-Pub 2015. PMID: 25589497.
116. Lee HJ, Song IH, Seo AN, Lim B, Kim JY, Lee JJ, Park IA, Shin J, Yu JH, Ahn JH, Gong G. Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy. Ann Surg Oncol 22(2):392-400, 2015. e-Pub 2015. PMID: 25192679.
117. Ma, Y, Hao, S, Wang, S, Zhao, Y, Lim, B, Lei, M, Spector, DJ, El-Deiry, WS, Zheng, SY, Zhu, J. A combinatory strategy for detection of live CTCs using microfiltration and a new telomerase-selective adenovirus. BMJ open 5(2), 2015. e-Pub 2015. PMID: 25589497.
118. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 6(12):1306-19, 2015. e-Pub 2015. PMID: 26640591.
119. El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 16(12):0, 2015. e-Pub 2015. PMID: 26553611.
120. Lim B, Jiang Y. Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease". Curr Clin Pharmacol 10(4):267-78, 2015. e-Pub 2015. PMID: 26548904.
121. Brennan M, Lim B. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. Adv Exp Med Biol 867:327-37, 2015. e-Pub 2015. PMID: 26530375.
122. Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets 25(9):1-15, 2015. e-Pub 2015. PMID: 26004811.
123. Kim MC, Lee HJ, Lim B, Ha KT, Kim SY, So I, Kim BJ. Quercetin induces apoptosis by inhibiting MAPKs and TRPM7 channels in AGS cells. Int J Mol Med 33(6):1657-63, 2014. e-Pub 2014. PMID: 24647664.
124. Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat 145(3):615-23, 2014. e-Pub 2014. PMID: 24820412.
125. Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther 14(8):711-9, 2013. e-Pub 2013. PMID: 23792567.
126. Lim, B, Henry, D. Stroke syndrome secondary to hypercoagulability of lung cancer. Community Oncology 5(11):595-596, 2008. e-Pub 2008.
127. Seth S, Yam C, Huo L, Lim B, Rinkenbaugh AL, White JB, Ravenberg EE, Song X, Litton JK, Tripathy D, Valero V, Damodaran S, Arun B, Ueno NT, Lucci A, Thompson AM, Mittendorf EA, Rauch GM, Adrada B, Candelaria RP, Ding Q, Powell RT, Abuhadra NK, Zhang J, Futreal A, Draetta GF, Piwnica-Worms H, Symmans WF, Chang JT, Moulder SL. The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer. Breast Cancer Research. PMID: 42093035.

Invited Articles

1. Finnberg NK, Lim B. Predicting response to EGFR-targeting mAb in CRC – is the KRAS mutation test sufficient?. PMO 2(8):430-6, 2013. e-Pub 2013.

Review Articles

1. Hwang IS, Kim CW, Kim BR, Lim BR, Choi JH. A Comparative Analysis of Aroma Profiles of Soju and Other Distilled Spirits from Northeastern Asia. Foods 13(21), 2024. e-Pub 2024. PMID: 39517153.
2. Mouabbi, JA, Hassan, A, Lim, B, Hortobagyi, GN, Tripathy, D, Layman, RM. Invasive lobular carcinoma. Breast Cancer Research and Treatment 193(2):253-264, 2022. e-Pub 2022. PMID: 35347549.
3. Singh, P, Lim, B. Targeting Apoptosis in Cancer. Current oncology reports 24(3):273-284, 2022. e-Pub 2022. PMID: 35113355.
4. Hobbs, EA, Chen, N, Kuriakose, A, Bonefas, E, Lim, B. Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer. Therapeutic Advances in Medical Oncology 14, 2022. e-Pub 2022. PMID: 35860831.
5. Chainitikun, S, Fernandez, JE, Long, JP, Iwase, T, Kida, K, Wang, X, Saleem, S, Lim, B, Valero, V, Ueno, NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer. PloS one 16(4 April), 2021. e-Pub 2021. PMID: 33861773.
6. Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers (Basel) 12(9):1-19, 2020. e-Pub 2020. PMID: 32883032.
7. Lim B, Lin Y, Navin N. Advancing Cancer Research and Medicine with Single-Cell Genomics. Cancer Cell 37(4):456-470, 2020. e-Pub 2020. PMID: 32289270.
8. Lim, B, Greer, YE, Lipkowitz, S, Takebe, N. Novel apoptosis-inducing agents for the treatment of cancer, a new arsenal in the toolbox. Cancers 11(8), 2019. e-Pub 2019. PMID: 31370269.
9. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31137625.
10. Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer 18(8):485-499, 2018. e-Pub 2018. PMID: 29703913.
11. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am 98(4):787-800, 2018. e-Pub 2018. PMID: 30005774.
12. Le-Petross HT, Lim B. Role of MR Imaging in Neoadjuvant Therapy Monitoring. Magn Reson Imaging Clin N Am 26(2):207-220, 2018. e-Pub 2018. PMID: 29622126.
13. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228-e232, 2017. e-Pub 2017. PMID: 28368261.
14. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget 6(15):12890-12908, 2015. e-Pub 2015. PMID: 25973541.
15. Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Res 3:198, 2014. e-Pub 2014. PMID: 25400908.
16. Lim B, Cream LV, Harvey HA. Update on clinical trials: genetic targets in breast cancer. Adv Exp Med Biol 779:35-54, 2013. e-Pub 2013. PMID: 23288634.

Professional Educational Materials

1. Milbury K, S-P W, Durrani S, Li Y, Whisenant M, Li J, Lim B. Educational Exchange. jpsmjournal.com, 2020.

Other Articles

1. Nicolò E, Bertucci F, Boussen H, Curigliano G, Fraser V, Gerratana L, Krishnamurthy S, Le-Petross HT, Lim B, Lynce F, Lucci A, Lucotti S, Manai M, Merajver S, Missal N, Nasrazadani A, Soliman A, Valenza C, Van Berckelaer C, Van Laere S, Woodward WA, Cristofanilli M, Devi G Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025. Cancer 132(10), 2026. PMID: 42133847.
2. Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Author Correction. Nature communications 15(1), 2024. PMID: 38965214.
3. Shafaee, MN, Makawita, S, Lim, B, Ellis, MJ, Ludwig, MS Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer. Clinical breast cancer 22(4):e536-e543, 2022. PMID: 35184934.
4. Allen, JE, Leah, C, Prabhu, VV, Wagner, J, Ishizawa, J, Madhukar, N, Lev, A, Baumeister, M, Zhou, L, Lulla, A, Stogniew, M, Schalop, L, Benes, CH, Kaufman, HL, Pottorf, RS, Rao Nallaganchu, B, Olson, GL, Al-Mulla, F, Duvic, M, Wu, GS, Dicker, DT, Talekar, M, Lim, B, Elemento, O, Oster, W, Bertino, JR, Flaherty, KT, Wang, L, Borthakur, G, Andreeff, M, Stein, MN, El-Deiry, WS Erratum. Oncotarget 12(21):2231, 2021. PMID: 34676056.
5. Lim, B, Woodward, W, Wang, X, Reuben, JM, Ueno, NT Erratum to. Nature Reviews Cancer 18(8):526, 2018. PMID: 29748602.
6. Lim B Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From The ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Breast Diseases: a YB Quarterly 26(3), 2015.
7. Lee J, Lim B, Ueno NT VOICES: MD Anderson's EDGE Preclinical Solutions Program—Aiming to Overcome Challenges of Preclinical Research for Breast Cancer Early Drug Development. Oncology Times 37(24):36-7, 2015.

Editorials

1. Kalra R, Lim B, Ellis MJ, Kavuri SM. The uncharted role of HER2 mutant alleles in breast cancer. Oncotarget 14(1):904-907, 2023. PMID: 37921670.
2. Msaouel, P, Jiménez-Fonseca, P, Lim, B, Carmona-Bayonas, A, Agnelli, G. Medicine before and after David Cox. European Journal of Internal Medicine 98:1-3, 2022. PMID: 35241350.
3. Hester, R, Hortobagyi, GN, Lim, B. Inflammatory breast cancer. American journal of obstetrics and gynecology 225(4):392-396, 2021. PMID: 33845027.
4. Lim, B. PD-L1 in Breast Cancer. Journal of the National Cancer Institute 113(8):951-952, 2021. PMID: 33523229.

Abstracts

1. Lopez ER, Alexander A, Marx A, Li X, Knafl M, Woodman SE, Cao J, Liu S, Darbonne W, Woodward WA, Valero V, Lim B. Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states, 2026.
2. Lim B. Abstract PS4-07-22: Chemotherapy Decision Making and Outcomes in Very Early-Stage Triple Negative Breast Cancer. SABCS 2025(4_Supplemental), 2026.
3. Lim B. Abstract PS4-01-10: Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast Cancer. SABCS 2025(4_supplemental), 2026.
4. Lim B. Abstract PS1-07-23: Outcome After Locoregional Recurrences For Definitively Treated Non-Metastatic Inflammatory Breast Cancer. SABCS 2025(4_supplemental), 2026.
5. Lim B. Abstract PS2-04-23: Poor response to systemic therapy upon progression on cyclin dependent kinase 4/6 inhibitors in HR+ Inflammatory Breast Cancer. SABCS 2025(4_supplemental), 2026.
6. Lim B. Abstract PD5-07: Prospective Analysis of Circulating Tumor Cell Clearance and Dynamics with Adjuvant Radiotherapy in Locally Advanced Breast Cancer. SABCS 2025(4_supplemental), 2026.
7. Lim B. Abstract PS3-04-17: Deep Learning Classification of Inflammatory Breast Cancer Using Multiparametric MRI: A Multi-Sequence Analysis. SABCS 2025(4_supplmental), 2026.
8. Lim B. Abstract PS3-07-21: Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). SABCS 2025, 2026.
9. Lim B. Abstract PS3-04-27: Mutational burden and clonal expansion in lymph nodes correlate with IBC postoperative relapse. SABCS 2025(4_Supplemental), 2026.
10. J Mouabbi, P pohlmann, B Lim, RA Mukhtar, D Grachev, B Baranov, C Chalabyan, D Goncharova, P Turova, K Chernyshov, V Kushnarev, F Paradiso, J Litton, R Layman, F Meric-Bernstam, J Rodon. Abstract PS2-10-30: Tumor-associated macrophage (TAMs) and cancer-associated fibroblasts (CAFs) profiles in invasive lobular carcinoma (ILC) vs no special type (NST). SABCS 2025(4_Supplment):PS2-10-30, 2026.
11. Lim B. Abstract PD2-02: Stability of Estrogen receptor (ER), Progesterone receptor (PR), and Human epidermal growth factor receptor 2 (HER2) in Residual Invasive Tumor after Neoadjuvant Therapy in Inflammatory Breast Cancer. SABCS 2025(4_supplemental), 2026.
12. Lim B. Abstract PS1-09-12: Trop2 expression and therapeutic opportunities in inflammatory breast cancer. SABCS 2025, 2026.
13. Upadhyay R, Alexander A, Ye Q, Chen K, Yam C, Hogan GJ, Zhang S, LaBella ML, Ratzel S, Cancer Team TMIB, Lucci A, Woodward WA, Lim B. Abstract PS4-02-02: Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer. SABCS 2025(4_Supplemental). e-Pub 2026.
14. Lim B. Abstract 6188: Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy. American Association For Cancer Research. e-Pub 2026.
15. Lim B. Abstract 1181: Transcriptomic analysis of NDRG1 amplification in aggressive breast cancer. American Association For Cancer Research. e-Pub 2026.
16. Lim B. Abstract 2259: Reprogramming of the stromal and immune microenvironment in preinvasive breast cancer. American Association For Cancer Research. e-Pub 2026.
17. Lim B. Abstract 4110: Genomic vulnerabilities and clinical behavior of metaplastic breast cancer through integrated registry and GENIE analysis. American Association For Cancer Research. e-Pub 2026.
18. Lim B. Abstract 7440: Characterization of the metastatic TIME via spatial transcriptomics reveals unique cellular phenotypes post anti-CSF-1R and immuno-chemotherapy. American Association For Cancer Research. e-Pub 2026.
19. Lim B. Abstract 3744: Peripheral immune indices predict pathologic complete response and residual cancer burden in inflammatory breast cancers. American Association For Cancer Research. e-Pub 2026.
20. Nasrazadani A, Tidwell R, Kai M, Lim B, Valero V, Saleem S, Lucci A, Cancer Team MIB, Woodward W, Layman RM. Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer, 2025. e-Pub 2025.
21. Lim B, Layman R, Valero V, Saleem S, Lucci A, Baranov O, Kushnarev V, Butusova A, Menshikova S, Gokin A, Novokreshenova A, Chernyshov K, Kotlov N, Cancer Team MIB, Woodward W, Lim B. Luminal subtype independent immune-enrichment in inflammatory breast cancer based on commercially available tumor portrait, 2025. e-Pub 2025.
22. Haney J, Pedroza DA, Marx A, Alexander A, Tidwell R, Nasrazadani A, Layman R, Valero V, Sun H, Lucci A, Sun S, Le-Petross C, Whitman G, Sheth R, Krishnamurthy S, Goodman C, Stauder M, Woodward WA, Rosen J, Lim B. A phase Ib study of novel combination (New) of low dose oral cyclophoSphamide (S) To potentiate axatilimab (A) + retifanlimab (R) in treating metastatic Triple negative breast cancer (NEW START), 2025. e-Pub 2025.
23. Chen J, Meas S, Bassett RL, Sarli VN, Upshaw J, Le-Petross HT, Valero V, Lim B, Woodward WA, Lucci A. Molecular Residual Disease Precedes Radiographic Confirmation of Recurrence in Patients with Stage III Inflammatory Breast Cancer, 2025. e-Pub 2025.
24. Lim B, Jia L, Sudheendra PK, Hirshfield KM. LITESPARK-029: A Phase 2, Randomized, Open-label Study of Belzutifan Plus Fulvestrant in Patients W/ Estrogen Receptor Pos, HER2-Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy, 2025. e-Pub 2025.
25. Nasrazadani A, Tidwell R, Kai M, Layman RM, Lim B, Valero V, Saleem S, Lucci A, Stauder M, Sun SX, Cancer Team MIB, Woodward W. 1000 Patient Prospective Inflammatory Breast Cancer (IBC) Registry Demonstrates Advances in Outcomes for IBC, 2025. e-Pub 2025.
26. Le-Petross H, Son JB, Ma J, Kai M, Whitman G, Guirguis M, Patel M, Kapoor M, Sun S, Lim B, Alexander A, Valero V, Lucci A, Woodward W. Quantitative Diffusion Weighted Imaging for Predicting Response to Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer, 2025. e-Pub 2025.
27. Krishnamurthy S, Bassett RL, Jr, Nasrazadani A, Layman RM, Lim B, Sun SX, Kai M, Ueno N, Tripathy D, Valero V, Lucci A, Woodward W, Cancer Team MIB. Development and validation of Residual tumor Burden calculator specific for Inflammatory breast carcinoma (IBC) to predict outcome (R-IBC), 2025. e-Pub 2025.
28. Le-Petross H, Kai M, Marx AN, Murphy H, Alexander A, Whitman G, Saleem S, Guirguis M, Patel M, Sun S, Lim B, Valero V, Lucci A, Cancer Team MIB, Woodward W. The Impact of a Multidisciplinary Quality Assurance Conference on the Management of Inflammatory Breast Cancer, 2025. e-Pub 2025.
29. Zhen ZY, Chen A, Jaehnig E, Anurag M, Lei J, Wang C, Feng L, Singh P, Kennedy H, Cao J, Yadav G, Tsai J, Chen X, Foulds C, Lim B, Ellis M, Zhang B, Chang E. Abstract GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer 84(9_Suppl):GS01-08, 2024. e-Pub 2024.
30. Baek L, Dobrolecki L, Faucher S, Sallas C, Griffith N, Prabhu V, Lim B, Lewis M, Echeverria G. Abstract PO1-29-01: Single agent and combinatorial efficacy with imipridone ONC206 via inhibition of mitochondrial function in preclinical models of chemorefractory triple negative breast cancer 84(9_Suppl):PO1-29-01, 2024. e-Pub 2024.
31. Alexander A, Murphy H, Reuben J, Le-Petross HT, Lane D, Huang M, Krishnamurthy S, Gong Y, Gombos D, Patel N, Allen R, Liu S, Patel A, Futreal A, Wistuba I, Layman R, Ueno NT, Tripathy D, Lim B, Valero V. Abstract PO5-06-02: Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory breast cancer 84(9_Suppl):P05-06-02, 2024. e-Pub 2024.
32. Nasrazadani A, Slack R, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Lucci A, Woodward W, Layman R. Poor response to cyclin dependent kinase 4/6 inhibition in metastatic inflammatory breast cancer 9(4_Suppl):103244, 2024. e-Pub 2024.
33. Nasrazadani A, Kai M, Layman R, Valero V, Saleem S, Debeb BG, Lucci A, Sun SX, Bopparaju S, Murphy HE, Alexander A, Marx AN, Stauder MC, Lim, Woodward WA. High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy 84(6_Suppl):4852, 2024. e-Pub 2024.
34. Yan Y, Lin Y, Kumar T, Bai S, Li J, Tran T, Hu M, Ravenberg E, Rauch M, Clayborn A, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the archetypes and eco-hubs of triple-negative breast cancer in responses to chemotherapy 84(6_Suppl):6933, 2024. e-Pub 2024.
35. Lin Y, Wang J, Wang K, Bai S, Thennavan A, Wei R, Yan Y, Li J, Elgamal H, Sei E, Casasent A, Rao M, Tang C, Montalvan J, Nagi C, Winocour S, Lim B, Thompson A, Navin N. Normal breast tissues harbor rare populations of aneuploid epithelial cells 84(6_Suppl):780, 2024. e-Pub 2024.
36. Kim BJ, Zhen ZY, Lei J, Holt M, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Duo Y, Chica-Parrado MR, Bikorimana E, Y D, Wang Y, Hanger A, Mohamed N, Hilsenbeck S, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis M, Chang E. Abstract PO2-14-11: Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment 84(9_Suppl), 2024. e-Pub 2024.
37. Iwase T, Alenxander A, Cohen EN, Gao H, Chiv VY, Kai M, Kida K, Krishnamurthy S, Liu D, Shen Y, Ramirez DL, Reuben A, Tripathy D, Booser DJ, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer 41(16_Suppl), 2023. e-Pub 2023.
38. Sun J, Marx A, Alexander A, Willey J, Kai M, Valero V, Lim B. A combination of circulating tumor cell (CTC) and cancer stem cell (CSC) markers to predict the prognosis of breast cancer 41(16_Suppl), 2023. e-Pub 2023.
39. Alexander A, Marx A, Wiley J, Kai M, Valero V, Woodward WA, Tin T, Kalashnikova E, Bristow SL, Renner D, Wu HT, Donahue J, Rodriguez AA, Sethi H, Liu MC, George MA, Cristofanilli M, Lim B. ctDNA detection before and during systemic therapy for inflammatory breast cancer 41(16_Suppl), 2023. e-Pub 2023.
40. Wank K, Xiao Z, Lin Y, Wei R, Ye R, Hu M, Bai S, Sei E, Thennavan A, Lim B, Futreal A, Thompson A, Krishnamurthy S, Navin N. Reprogramming of the preinvasive breast microenvironment identified by spatial nucleus barcoding 83(7_Suppl):76, 2023. e-Pub 2023.
41. Dai Y, Cao S, Lim B, Staaf J, Echeverria GV, Wang W. Tumor cell total mRNA level predicts disease progression across multi-ethnic patient cohorts with triple-negative breast cancer 83(7_Suppl):3311, 2023. e-Pub 2023.
42. Baek L, Lee J, Pendleton KE, Berner MJ, Goff E, Tan L, Martinez S, Mahmud I, Arriojas A, Zhurkevich A, Wang T, Meyer M, Lim B, Barrish JP, Porter W, Zarringhalam K, Lorenzi PL, Echeverria GV. Abstract P6-11-14: Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment 83(5_Suppl):P6-11-14, 2023. e-Pub 2023.
43. Shah AN, Lim B, Mita MM, Mauer E, Layng KV, Chao C, Brufsky AM. Abstract P2-23-12: The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors 83(5_Suppl):P2-23-12, 2023. e-Pub 2023.
44. Chang E, Tsai J, Lim B. Abstract P5-05-03: Characterization of the genomic landscape of breast carcinoma patients with NF1 alterations using comprehensive cell-free tumor DNA next-generation sequencing 83(5_Suppl):P5-05-03, 2023. e-Pub 2023.
45. Machado Heredia ML, Kuriakose A, Menegaz BA, Thompson AM, Lim B, Javaid H. Abstract P6-08-03: Barriers to enrolling in observational trials for patients with stage IV breast cancer 83(5_Suppl):P6-08-03, 2023. e-Pub 2023.
46. Chen N, Wang D, Porter CE, Shaw AR, Robertson CR, Woods ML, Xu Y, Biegert G, Kuriakose A, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki M, Lim B. Abstract P3-06-04: Treatment of Metastatic Breast Cancer with Multipotent Oncolytic/Helper Adenovirus CAdVEC 83(5_Suppl):P3-06-04, 2023. e-Pub 2023.
47. Iwase T, Alexander A, Chiv V, Kai M, Kida K, Parker C, Marx AN, Cohen E, Gao H, Reuben J, Wang X, Krishnamurthy S, Liu D, Shen Y, Ramirez D, Tripathy D, Booser D, Yam C, Valero V, Lim B, Ueno NT, Willey JS. Abstract P3-02-04: Phase II study of pembrolizumab maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) 83(5_Suppl):P3-02-04, 2023. e-Pub 2023.
48. Marx AN, Kai M, Fu M, Murphy HE, Willey JS, Sun H, Alexander A, Bassett RL, Whitman GJ, Le-Petross HTC, Patel M, Arun BK, Abouharb S, Thomas PS, Barcenas CH, Ibrahim NK, Valero V, Ueno NT, Layman RM, Lim B, Woodward W, Lucci A. Abstract P4-06-09: A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2+ primary breast cancer 83(5_Suppl):P4-06-09, 2023. e-Pub 2023.
49. Lim B, Alexander A, Willey JS, Sun H, Liu S, Patel AB, Parra ER, Haymaker C, Soto LS, Serrano A, Sun B, Pinto LIma CF, Tamegnon A, Pandurengan RK, Douse D, Lan J, Raja L, Chu R, Knafl M, Woodman SE, Zhu H, Shulze K, Fedenko K, Darbonne W, Ueno NT, Valero V. Abstract P4-08-19: Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab+ cobimetinib+ eribulin in patients with HER2+ breast cancer 83(5_Suppl):P4-08-29, 2023. e-Pub 2023.
50. Seker S, Oropeza E, Carrel S, Muzumder A, Punturi N, Lei J, Anurag M, Lim B, Bainbridge M, Haricharan S. Abstract P3-10-02: Cell cycle dysregulation in breast cancer: why the details matter 83(5_Suppl):P3-10-02, 2023. e-Pub 2023.
51. Baek L, Lee J, Berner MJ, Pendleton KE, Goff EB, Wang K, Barrish JP, Lim B, Lorenzi PJ, Porter W, Lewis MT, Echeverria GV. Morphological and functional plasticity of mitochondria promotes chemotherapy resistance in triple negative breast cancer 82(12_Suppl):6384, 2022. e-Pub 2022.
52. Minussi DC, Wang J, Schalck A, Yan Y, Wu HJ, Peng C, Hu M, Sei E, Edgerton M, Chen H, Contreras A, Hui D, Damodaran S, Kopetz S, Lim B, Navin N. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit 82(12_Suppl):1210, 2022. e-Pub 2022.
53. Anurag M, Jaehnig E, Lei J, Kim BJ, Tran Huynh AM, Dou Y, Vashist T, Bergstrom E, Gou X, Korchina V, Muzny DM, Otte K, Doddapaneni H, Dobrolecki L, Echeverria GV, Lim B, Rimawi M, Krug K, Hageman I, Rodriguez H, Robles AI, Hiltke T, Osborne K, Gillette M, Miles G, Carr S, Lewis MT, Zhang B, Ademuyiwa F, Satpathy S, Ellis MJ. LIG1 deletion predicts chemotherapy resistance, chromosomal instability, and poor prognosis in triple negative breast cancer 82(12_Suppl):1010, 2022. e-Pub 2022.
54. Lim B, Jia L, Sudheendra PK, Hirshfield KM. LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy, 2021. e-Pub 2021.
55. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Pitpitan R, Arun B, White JB, Ravenberg E, Santiago L, Sahin AA, Murthy RK, Ueno NT, Ibrahim NK, Mloulder SL, Huo L. The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL). Ann Oncol 31(Suppl_2), 2020. e-Pub 2020.
56. Lim B, Seth S, Huo L, Layman RM, Valero V, Thompson AM, White JB, Litton JK, Damodaran S, Candelaria RP, Arun B, Rauch GM, Murthy RK, Ding Q, Symmans WF, Zhao L, Zhang J, Tripathy D, Moulder SL, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT)+/-enzalutamide 38(15_Suppl), 2020. e-Pub 2020.
57. Moulder SL, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). J Clin Oncol 38(15_suppl):595, 2020. e-Pub 2020.
58. Lim B, Seth S, Huo L, Layman RM, Valero V, Thompson AM, White JB, Litton JK, Damodaran S, Candelaria RP, Arun B, Rauch GM, Murthy RK, Ding Q, Symmans WF, Zhao L, Zhang J, Tripathy D, Moulder SL, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT)+/-enzalutamide. J Clin Oncol 38(15_Suppl), 2020. e-Pub 2020.
59. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Pitpitan R, Arun B, White JB, Ravenberg E, Santiago L, Sahin AA, Murthy RK, Ueno NT, Ibrahim NK, Mloulder SL, Huo L. The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL) 31(Suppl_2), 2020. e-Pub 2020.
60. Moulder SL, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC) 38(15_suppl):595, 2020. e-Pub 2020.
61. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, White JB, Ravenberg E, Damodaran S, Candelaria RP, Arun B, Ueno NT, Santiago L, Murhy RK, Ibrahim NK, Symmans WF, Moulder SL, Huo L. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC) 38(15_Suppl), 2020. e-Pub 2020.
62. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, White JB, Ravenberg E, Damodaran S, Candelaria RP, Arun B, Ueno NT, Santiago L, Murhy RK, Ibrahim NK, Symmans WF, Moulder SL, Huo L. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). J Clin Oncol 38(15_Suppl), 2020. e-Pub 2020.
63. Basho RK, Yam C, White JB, Zhao L, Huo L, Mittendorf EA, Thompson AM, Litton JK, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Moulder SL, Damodaran S. Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes 38(15_Suppl), 2020. e-Pub 2020.
64. Basho RK, Yam C, White JB, Zhao L, Huo L, Mittendorf EA, Thompson AM, Litton JK, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Moulder SL, Damodaran S. Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. J Clin Oncol 38(15_Suppl), 2020. e-Pub 2020.
65. Evans K, Moulder S, Yuca E, Scott S, Arango NP, Shariati M, Vellano CP, Saridogan T, Zheng X, Gonzalez-Argulo AM, Zhao M, Su X, Tapia C, Chen K, Akcakanat A, Perou CM, Lim B, Tripathy D, Yap TA, Francesco ME, Draetta PJ, Marszalek J, Meric-Bernstam F. Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer 18(C016), 2019. e-Pub 2019.
66. Yennu S, Valero V, Lim B, Booser DJ, Diaz Hernandez C, Lu Z, Liu DD, Busaidy NL, Reuben JM, Williams JL, Hess KR, Basen Engquist K, Bruera E. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study 37(31_Suppl), 2019. e-Pub 2019.
67. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant chemotherapy. J Clin Oncol 37(15_Suppl), 2019. e-Pub 2019.
68. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. J Clin Oncol 37(15_Suppl), 2019. e-Pub 2019.
69. Winer A, Vijayvergia N, Cohen SJ, Denlinger CS, Astsaturov IA, Dotan E, J-N G, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik JM, Zhou L, Korzekwa K, Ruth K, Ross EA, El-Deiry WS. A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer. J Clin Oncol 37(15_Suppl), 2019. e-Pub 2019.
70. Crespo J, Sun H, Wu J, Ding Q, Tang G, Robinson M, Chen H, Sahin AA, Lim B. HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification. J Clin Oncol 37(15_Suppl), 2019. e-Pub 2019.
71. Yennu S, Valero V, Lim B, Booser DJ, Hernandez CDH, Lu Z, Liu DD, Busaidy NL, Reuben JM, Williams JL, Hess KR, Basen-Enuquist KB, Bruera E. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study 37(15_Suppl), 2019. e-Pub 2019.
72. Winer A, Vijayvergia N, Cohen SJ, Denlinger CS, Astsaturov IA, Dotan E, J-N G, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik JM, Zhou L, Korzekwa K, Ruth K, Ross EA, El-Deiry WS. A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer 37(15_Suppl), 2019. e-Pub 2019.
73. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC 37(15_Suppl), 2019. e-Pub 2019.
74. Crespo J, Sun H, Wu J, Ding Q, Tang G, Robinson M, Chen H, Sahin AA, Lim B. HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification 37(15_Suppl), 2019. e-Pub 2019.
75. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant chemotherapy 37(15_Suppl), 2019. e-Pub 2019.
76. Yennu S, Valero V, Lim B, Booser DJ, Hernandez CDH, Lu Z, Liu DD, Busaidy NL, Reuben JM, Williams JL, Hess KR, Basen-Enuquist KB, Bruera E. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study. J Clin Oncol 37(15_Suppl), 2019. e-Pub 2019.
77. Karakas B, Jean SR, Narovlyansky M, Kumar S, Gillies S, Krajewski S, Lim B, Cardone M. Identifying Bcl-2 family protein dependencies in tumors using dimerization specific antibody biomarkers as a method for predicting response to apoptosis inducing therapies 79(13_suppl):3164, 2019. e-Pub 2019.
78. Karakas B, Jean SR, Narovlyansky M, Kumar S, Gillies S, Krajewski S, Lim B, Cardone M. Identifying Bcl-2 family protein dependencies in tumors using dimerization specific antibody biomarkers as a method for predicting response to apoptosis inducing therapies. Cancer Res 79(13_suppl):3164, 2019. e-Pub 2019.
79. Moulder SL, Adrada B, Lim B, Ueno NT, Candelaria RM, Rauch G, Litton JK, Thompson AM, Huo L, Hess KR. A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response. The Breast 44:S101-102, 2019. e-Pub 2019.
80. Moulder SL, Adrada B, Lim B, Ueno NT, Candelaria RM, Rauch G, Litton JK, Thompson AM, Huo L, Hess KR. A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response 44:S101-102, 2019. e-Pub 2019.
81. Alexander A, Marx AN, Reddy SM, Ruben JM, Le-Petross HC, Lane D, Huang ML, Krishnamurthy S, Gong Y, Gombos DS, Patel N, Tung CI, Allen RC, Kandl TJ, Wu J, Liu S, Patel AB, Futreal A, Wistuba I, Layman RM, Valero V, Tripathy D, Ueno NT, Lim B. Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC) 79(4 Suppl), 2019. e-Pub 2019.
82. Masuda H, Miura S, Harano K, Wang Y, Hirota Y, Matsunaga Y, Lim B, Lucci A, Parinyanitikul N, Lee HJ, Gong G, Rao A, Seitz RS, Morris SW, Hout DR, Nakamura S, Tripathy D, Harada O, Krishnamurthy S, Ueno NT. Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy. Cancer Res 79(4_Suppl), 2019. e-Pub 2019.
83. Ueno NT, Tahara RK, Reuben JM, Gao H, Saigal B, Fujii T, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, BA Chasen BA. Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis 79(4_Suppl), 2019. e-Pub 2019.
84. Kida K, Lee J, Liu H, Lim B, Murthy RK, Sahin AA, Tripathy D, Ueno NT. Abstract P3-10-23: Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab 79(4_Suppl), 2019. e-Pub 2019.
85. Alexander A, Marx AN, Reddy SM, Ruben JM, Le-Petross HC, Lane D, Huang ML, Krishnamurthy S, Gong Y, Gombos DS, Patel N, Tung CI, Allen RC, Kandl TJ, Wu J, Liu S, Patel AB, Futreal A, Wistuba I, Layman RM, Valero V, Tripathy D, Ueno NT, Lim B. Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC). Cancer Res 79(4 Suppl), 2019. e-Pub 2019.
86. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. Cancer Res 79(4_Suppl), 2019. e-Pub 2019.
87. H Masuda H, S Miura S, K Harano K, Y Wang Y, Y Hirota Y, Y Matsunaga Y, Lim B, A Lucci A, N Parinyanitikul N, HJ Lee HJ, G Gong G, A Rao A, RS Seitz RS, SW Morris SW, DR Hout DR, S Nakamura S, D Tripathy D, O Harada O, S Krishnamurthy S, NT Ueno NT. Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy 79(4_Suppl), 2019. e-Pub 2019.
88. Kida K, Lee J, Liu H, Lim B, Murthy RK, Sahin AA, Tripathy D, Ueno NT. Abstract P3-10-23: Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab. Cancer Res 79(4_Suppl), 2019. e-Pub 2019.
89. Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. Cancer Res 79(4_Suppl), 2019. e-Pub 2019.
90. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy 79(4_Suppl), 2019. e-Pub 2019.
91. Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy 79(4_Suppl), 2019. e-Pub 2019.
92. Ueno NT, Tahara RK, Reuben JM, Gao H, Saigal B, Fujii T, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis. Cancer Res 79(4_Suppl), 2019. e-Pub 2019.
93. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience 18(6), 2018. e-Pub 2018.
94. Chang N, Chen H, Al-Awadhi AM, Tang G, Robinson MK, Lim B, Sahin A. Equivocal HER2/neu FISH Results in Breast Cancer: How Frequently Do They Change on Repeat Testing? 98:53, 2018. e-Pub 2018.
95. Espinosa-Fernandez JR, Eckhardt BL, Lee J, Seitz RS, Hout DR, Ring BZ, Lim B, Ueno NT. Abstract P5-06-04: Classification of molecular subtypes of triple-negative breast cancer cell lines using two models 78(4_Suppl), 2018. e-Pub 2018.
96. Al-Awadhi A, Kono M, Marx A, Moseley T, Willey J, Sun H, Fu M, Whitman GJ, Valero V, Ueno NT, Lim B. Abstract OT2-07-09: A phase Ib study of neratinib, pertuzumab, and trastuzumab with paclitaxel in patients with metastatic and locally advanced breast cancer. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
97. Willey JS, Parker C, Valero V, Lim B, Reuben JM, Krishnamurthy S, Gong Y, Scoggins ME, Dryden MJ, Liu DD, Woodward WA, Ueno NT. Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
98. Alexander A, Willey J, Sun H, Parker CA, Marx AN, Wood AL, Reddy SM, Reuben JM, Bassett RL, Le-Petross HT, Krishnamurthy S, Gong Y, Woodward WA, Valero V, Ueno NT, Lim B. A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer. Cancer Res 78(4 Suppl), 2018. e-Pub 2018.
99. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
100. Willey JS, Marx AN, Lim B, Ibrahim NK, Valero V, Mittendorf EM, Reuben JM, Le-Petross HT, Whitman GJ, Krishnamurthy S, Woodward WA, Lucci A, Liu DD, Shen Y, Ueno NT. Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
101. Willey JS, Parker C, Valero V, Lim B, Reuben JM, Krishnamurthy S, Gong Y, Scoggins ME, Dryden MJ, Liu DD, Woodward WW, Ueno NT. Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (TNBC). Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
102. Willey J, Parker C, Lim B, Valero V, Le-Petross HT, Krishnamurthy S, Woodward WA, Lucci A, Wood AL, Sun H, Babiera GV, Song J, Shen Y, Wang X, Ueno NT. Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab/carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
103. Cohen EN, Jayachandran G, Gao H, Tin S, Alvarez RH, Valero V, Lim B, Ueno NT, Reuben J. Abstract P2-02-04: Circulating protein biomarker profile for inflammatory breast cancer using a multiplexed proximity extension assay. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
104. Alexander A, Willey J, Sun H, Parker CA, Marx AN, Wood AL, Reddy SM, Reuben RM, Bassett RL, Le-Petross CH, Krishnamurthy S, Gong Y, Woodward WA, Valero V, Ueno NT, Lim B. Abstract OT1-02-05: A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive inflammatory breast cancer. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
105. Lee J, Lim B, Pearson T, Tripathy D, Ordentlich P, Ueno NT. Abstract P5-21-15: The synergistic antitumor activity of entinostat (MS-275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative …. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
106. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, EA Mittendorf EA, NT Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Abstract P1-07-22: Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
107. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria B, Wang H, Leung J, Thompson AM, Litton JK, Wu Y, Lim B, Moulder SL, Mittendorf EA, Yang W. Abstract P4-02-04: Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
108. Espinosa-Fernandez JR, Eckhardt BL, Lee J, Seitz RS, Hout DR, Ring BZ, Lim B, Ueno NT. Abstract P5-06-04: Classification of molecular subtypes of triple-negative breast cancer cell lines using two models. Cancer Res 78(4_Suppl), 2018. e-Pub 2018.
109. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer 78(4_Suppl), 2018. e-Pub 2018.
110. Alexander A, Willey J, Sun H, Parker CA, Marx AN, Wood AL, Reddy SM, Reuben RM, Bassett RL, Le-Petross CH, Krishnamurthy S, Gong Y, Woodward WA, Valero V, Ueno NT, Lim B. Abstract OT1-02-05: A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive inflammatory breast cancer 78(4_Suppl), 2018. e-Pub 2018.
111. Willey JS, Parker C, Valero V, Lim B, Reuben JM, Krishnamurthy S, Gong Y, Scoggins ME, Dryden MJ, Liu DD, Woodward WW, Ueno NT. Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (TNBC) 78(4_Suppl), 2018. e-Pub 2018.
112. Willey J, Parker C, Lim B, Valero V, Le-Petross HT, Krishnamurthy S, Woodward WA, Lucci A, Wood AL, Sun H, Babiera GV, Song J, Shen Y, Wang X, Ueno NT. Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab/carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide 78(4_Suppl), 2018. e-Pub 2018.
113. Lee J, Lim B, Pearson T, Tripathy D, Ordentlich P, Ueno NT. Abstract P5-21-15: The synergistic antitumor activity of entinostat (MS-275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative … 78(4_Suppl), 2018. e-Pub 2018.
114. Alexander A, Willey J, Sun H, Parker CA, Marx AN, Wood AL, Reddy SM, Reuben JM, Bassett RL, Le-Petross HT, Krishnamurthy S, Gong Y, Woodward WA, Valero V, Ueno NT, Lim B. A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer 78(4 Suppl), 2018. e-Pub 2018.
115. Cohen EN, Jayachandran G, Gao H, Tin S, Alvarez RH, Valero V, Lim B, Ueno NT, Reuben J. Abstract P2-02-04: Circulating protein biomarker profile for inflammatory breast cancer using a multiplexed proximity extension assay 78(4_Suppl), 2018. e-Pub 2018.
116. Willey JS, Marx AN, Lim B, Ibrahim NK, Valero V, Mittendorf EM, Reuben JM, Le-Petross HT, Whitman GJ, Krishnamurthy S, Woodward WA, Lucci A, Liu DD, Shen Y, Ueno NT. Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence 78(4_Suppl), 2018. e-Pub 2018.
117. Willey JS, Parker C, Valero V, Lim B, Reuben JM, Krishnamurthy S, Gong Y, Scoggins ME, Dryden MJ, Liu DD, Woodward WA, Ueno NT. Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy 78(4_Suppl), 2018. e-Pub 2018.
118. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria B, Wang H, Leung J, Thompson AM, Litton JK, Wu Y, Lim B, Moulder SL, Mittendorf EA, Yang W. Abstract P4-02-04: Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer 78(4_Suppl), 2018. e-Pub 2018.
119. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, EA Mittendorf EA, NT Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Abstract P1-07-22: Androgen receptor positivity is associated with nodal disease in triple negative breast cancer 78(4_Suppl), 2018. e-Pub 2018.
120. Al-Awadhi A, Kono M, Marx A, Moseley T, Willey J, Sun H, Fu M, Whitman GJ, Valero V, Ueno NT, Lim B. Abstract OT2-07-09: A phase Ib study of neratinib, pertuzumab, and trastuzumab with paclitaxel in patients with metastatic and locally advanced breast cancer 78(4_Suppl), 2018. e-Pub 2018.
121. Meric-Bernstam F, Evans K, Zheng X, Su X, Yuca E, Scott S, Akcakanat A, Ueno NT, Lim B, Litton J, Valero V, Symmans WF, Hortobagyi G, Perou C, Tripathy D, Draetta G, Marszalek J, Gonzalez-Angulo AM, Moulder S. Oxidative phosphorylation as a target in triple negative breast cancer therapy 77(13 Suppl):4970, 2017. e-Pub 2017.
122. Jayachandran G, Cohen EN, Gao H, Alvarez RH, Valero V, Lim B, Woodward WA, Ueno NT, Reuben JM. Abstract P1-02-07: Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay. Cancer Res 77(4 Suppl):P1-02-07, 2017. e-Pub 2017.
123. Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno NT, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF. Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT). Cancer Res 77(4 Suppl):OT2-01-22, 2017. e-Pub 2017.
124. Fujii T, Lim B, Helgason T, Hess KR, Gilcrease MZ, Willey JS, Tripathy D, Litton JK, Moulder S, Krishnamurthy S, Yang W, Reuben JM, Symmans WF, Ueno NT. Abstract OT3-02-05: NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC). Cancer Res 77(4 Suppl):OT3-02-05, 2017. e-Pub 2017.
125. Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease MZ, Symmans WF, Huo L, Mittendorf EA, Thompson A, Moulder S, Tripathy D, Ueno NT. Abstract OT2-01-20: Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC). Cancer Res 77(4 Suppl):OT2-01-20, 2017. e-Pub 2017.
126. Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno NT, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF. Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) 77(4 Suppl):OT2-01-22, 2017. e-Pub 2017.
127. Damodaran S, Hess K, Rauch M, Astrada B, Santiago L, Litton J, Mittendorf M, Lim B, Ueno NT, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, Moulder SL. Abstract CT062: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy. Cancer Res 77(13 Suppl):CT062, 2017. e-Pub 2017.
128. Jayachandran G, Cohen EN, Gao H, Alvarez RH, Valero V, Lim B, Woodward WA, Ueno NT, Reuben JM. Abstract P1-02-07: Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay 77(4 Suppl):P1-02-07, 2017. e-Pub 2017.
129. Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease MZ, Symmans WF, Huo L, Mittendorf EA, Thompson A, Moulder S, Tripathy D, Ueno NT. Abstract OT2-01-20: Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC) 77(4 Suppl):OT2-01-20, 2017. e-Pub 2017.
130. Fujii T, Lim B, Helgason T, Hess KR, Gilcrease MZ, Willey JS, Tripathy D, Litton JK, Moulder S, Krishnamurthy S, Yang W, Reuben JM, Symmans WF, Ueno NT. Abstract OT3-02-05: NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC) 77(4 Suppl):OT3-02-05, 2017. e-Pub 2017.
131. Damodaran S, Hess K, Rauch M, Astrada B, Santiago L, Litton J, Mittendorf M, Lim B, Ueno NT, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, Moulder SL. Abstract CT062: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy 77(13 Suppl):CT062, 2017. e-Pub 2017.
132. Lim B, Lee J, Liu H, Pearson T, Coffer L, Tripathy D, Ueno NT. Preclinical evaluation of imipridone ONC201 in triple negative breast cancer identifies predictive biomarkers and combinatorial opportunities 77(13 Suppl):4294, 2017. e-Pub 2017.
133. Lim B, Lee J, Liu H, Pearson T, Coffer L, Tripathy D, Ueno NT. Preclinical evaluation of imipridone ONC201 in triple negative breast cancer identifies predictive biomarkers and combinatorial opportunities. Cancer Res 77(13 Suppl):4294, 2017. e-Pub 2017.
134. Meric-Bernstam F, Evans K, Zheng X, Su X, Yuca E, Scott S, Akcakanat A, Ueno NT, Lim B, Litton J, Valero V, Symmans WF, Hortobagyi G, Perou C, Tripathy D, Draetta G, Marszalek J, Gonzalez-Angulo AM, Moulder S. Oxidative phosphorylation as a target in triple negative breast cancer therapy. Cancer Res 77(13 Suppl):4970, 2017. e-Pub 2017.
135. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Woodward WA, Reuben JM, Ueno NT. Rates of immune inflitration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers. Cancer Res 76(14_Suppl), 2016. e-Pub 2016.
136. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Woodward WA, Reuben JM, Ueno NT. Rates of immune inflitration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers 76(14_Suppl), 2016. e-Pub 2016.
137. Moulder SL, Litton JK, Mittendorf EA, Yang W, Ueno NT, Hess KR, Valero V, Murthy RK, Ibrahim N, Lim B, Arun B, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Ann Oncol 27(Suppl_6), 2016. e-Pub 2016.
138. Diamond JR, Borges VF, Kabos P, Krill-Jackson E, Graham R, Hoffman A, Lim B, Richards D, Salkeni MA, Wilks S, Patel C, Neuwirth R, Kneissi M, Zohren F. Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane or fulvestrant in postmenopausal women with ER+/HER2- metastatic breast cancer. Ann Oncol 27(Suppl_6), 2016. e-Pub 2016.
139. Diamond JR, Borges VF, Kabos P, Krill-Jackson E, Graham R, Hoffman A, Lim B, Richards D, Salkeni MA, Wilks S, Patel C, Neuwirth R, Kneissi M, Zohren F. Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane or fulvestrant in postmenopausal women with ER+/HER2- metastatic breast cancer 27(Suppl_6), 2016. e-Pub 2016.
140. Moulder SL, Litton JK, Mittendorf EA, Yang W, Ueno NT, Hess KR, Valero V, Murthy RK, Ibrahim N, Lim B, Arun B, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease 27(Suppl_6), 2016. e-Pub 2016.
141. Lim B, Murthy RK, Jackson S, Willey J, Lee J, Alvarez, RH, karuturi MS, Barcenas CH, Ibrahim NK, Booser DJ, Moulder SL, Giordano SH, Brewster AM, Walters RS, Brown PH, Tripathy D, Valero V, Ueno NT. Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. J Clin Oncol 34(15_Suppl), 2016. e-Pub 2016.
142. Lim B, Murthy RK, Jackson S, Willey J, Lee J, Alvarez, RH, karuturi MS, Barcenas CH, Ibrahim NK, Booser DJ, Moulder SL, Giordano SH, Brewster AM, Walters RS, Brown PH, Tripathy D, Valero V, Ueno NT. Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab 34(15_Suppl), 2016. e-Pub 2016.
143. Fujii T, Kogawa T, Dong W, Litton JK, Moulder SL, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Shen Y, Lim B, Ueno NT. New threshold of ER positivity in early-stage HER2-negative breast cancer 34(15_Suppl), 2016. e-Pub 2016.
144. Fujii T, Kogawa T, Dong W, Litton JK, Moulder SL, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Shen Y, Lim B, Ueno NT. New threshold of ER positivity in early-stage HER2-negative breast cancer. J Clin Oncol 34(15_Suppl), 2016. e-Pub 2016.
145. Sato N, Wakabayashi M, Lee J, Lim B, Ueno NT, Ishihara H. Predicting the response of molecular targeting agents in triple-negative breast cancer cell lines by kinase activities 76(4_Suppl), 2016. e-Pub 2016.
146. Sato N, Wakabayashi M, Lee J, Lim B, Ueno NT, Ishihara H. Predicting the response of molecular targeting agents in triple-negative breast cancer cell lines by kinase activities. Cancer Res 76(4_Suppl), 2016. e-Pub 2016.
147. Mitri Z, Ueno NT, Yang W, Valero V, Litton J, Murthy R, Lim B, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Gilcrease M, Piwnica-Worms H, Tripathy D, Fraser WF, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvnat therapy 76(4_Suppl), 2016. e-Pub 2016.
148. Mitri Z, Ueno NT, Yang W, Valero V, Litton J, Murthy R, Lim B, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Gilcrease M, Piwnica-Worms H, Tripathy D, Fraser WF, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvnat therapy. Cancer Res 76(4_Suppl), 2016. e-Pub 2016.
149. Fujii T, Wang Y, Rao A, Lim B, Ueno NT, Le-Petross CH. A Pilot Study: Radiogenomics of Inflammatory Breast Cancer 76(14_Suppl), 2016. e-Pub 2016.
150. Fujii T, Wang Y, Rao A, Lim B, Ueno NT, Le-Petross CH. A Pilot Study: Radiogenomics of Inflammatory Breast Cancer. Cancer Res 76(14_Suppl), 2016. e-Pub 2016.
151. Yamauchi T, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Zujewski JA, Chen H, Takebe N, Saya H, Ueno NT. CD44v as a potential predictive biomarker for pathologic complete response in primary HER2+ breast cancer: Utility of adaptive response biopsy in preoperative therapy. Cancer Res 75(9_Suppl), 2015. e-Pub 2015.
152. Torres-Adorno AM, Lee JJ, Kogawa T, Bartholomeusz C, Pitner MK, Ordentlich P, Lim B, Tripathy D, Ueno NT. The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation 75(9_Suppl), 2015. e-Pub 2015.
153. Lim B, Summer J, Alvarez R, Ibrahim N, Willey J, Murthy RK, Booser D, Giordano S, Barcenas C, Brewster A, Walters R, Brown PH, Tripathy D, Valero V, Ueno NT. A single-center, open-label phase 1b study of entinostat and lapatinib alone, and in combination with trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab. Cancer Res 75(9_Suppl), 2015. e-Pub 2015.
154. Torres-Adorno AM, Lee JJ, Kogawa T, Bartholomeusz C, Pitner MK, Ordentlich P, Lim B, Tripathy D, Ueno NT. The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation. Cancer Res 75(9_Suppl), 2015. e-Pub 2015.
155. Lim B, Summer J, Alvarez R, Ibrahim N, Willey J, Murthy RK, Booser D, Giordano S, Barcenas C, Brewster A, Walters R, Brown PH, Tripathy D, Valero V, Ueno NT. A single-center, open-label phase 1b study of entinostat and lapatinib alone, and in combination with trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab 75(9_Suppl), 2015. e-Pub 2015.
156. Yamauchi T, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Zujewski JA, Chen H, Takebe N, Saya H, Ueno NT. CD44v as a potential predictive biomarker for pathologic complete response in primary HER2+ breast cancer: Utility of adaptive response biopsy in preoperative therapy 75(9_Suppl), 2015. e-Pub 2015.
157. Matsuda N, Alvarez RH, Krishnamurthy S, Willey JS, Wang X, Lim B, Parker CA, Marx A, Babiera G, Booser DJ, Murray JL, Arun B, Brewster AM, Reuben JM, Woodward WA, Lucci A, Gainer SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer 33(15_Suppl), 2015. e-Pub 2015.
158. French JT, Hess KR, Liu DD, Raghav KPS, Hortobagyi GN, Arun B, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer 33(15_Suppl), 2015. e-Pub 2015.
159. Fujii T, Kogawa T, Wei C, Fouad TM, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of body mass index with survival outcome in three breast cancer subtypes. J Clin Oncol 33(15_Suppl), 2015. e-Pub 2015.
160. Matsuda N, Alvarez RH, Krishnamurthy S, Willey JS, Wang X, Lim B, Parker CA, Marx A, Babiera G, Booser DJ, Murray JL, Arun B, Brewster AM, Reuben JM, Woodward WA, Lucci A, Gainer SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. J Clin Oncol 33(15_Suppl), 2015. e-Pub 2015.
161. French JT, Hess KR, Liu DD, Raghav KPS, Hortobagyi GN, Arun B, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. J Clin Oncol 33(15_Suppl), 2015. e-Pub 2015.
162. Fujii T, Kogawa T, Wei C, Fouad TM, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of body mass index with survival outcome in three breast cancer subtypes 33(15_Suppl), 2015. e-Pub 2015.
163. Lim B, Dicker DT, Kline LC, El-Deiry WS. Exploring the best therapeutic partner of triple negative breast cancers: using different characteristics/dependent pathways of triple negative breast cancer cell lines based on subgroups 73(24_Suppl), 2014. e-Pub 2014.
164. Lim B, Dicker DT, Kline LC, El-Deiry WS. Exploring the best therapeutic partner of triple negative breast cancers: using different characteristics/dependent pathways of triple negative breast cancer cell lines based on subgroups. Cancer Res 73(24_Suppl), 2014. e-Pub 2014.
165. Matthew E, Zhou L, Lim B, Lamparella NE, Dicker DT, J-N G, Joshi M, Holder SL, Harouaka R, Zheng S, Drabick JJ, Truica CI, Yang Z, El-Deiry WS. Immunophenotyping circulating tumor cells in patients with unknown primary. Cancer Res 73(24_Suppl), 2014. e-Pub 2014.
166. Matthew E, Zhou L, Lim B, Lamparella NE, Dicker DT, J-N G, Joshi M, Holder SL, Harouaka R, Zheng S, Drabick JJ, Truica CI, Yang Z, El-Deiry WS. Immunophenotyping circulating tumor cells in patients with unknown primary 73(24_Suppl), 2014. e-Pub 2014.
167. El-Deiry WS, Xiu J, Lim B, Scicchitano A, Feeley E, Harvey HA, Yee NS. Molecular Profiling of 6,892 Colorectal Cancer patients to identify potential treatment options. J Clin Oncol 32(15_Suppl), 2014. e-Pub 2014.
168. El-Deiry WS, Xiu J, Lim B, Scicchitano A, Feeley E, Harvey HA, Yee NS. Molecular Profiling of 6,892 Colorectal Cancer patients to identify potential treatment options 32(15_Suppl), 2014. e-Pub 2014.
169. Lim B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Elucidating the Change of TRAIL Sensitivity in Basal-Like TNBC Cell Lines by Lapatinib, and Further Therapeutic Implications 73(24_Suppl), 2013. e-Pub 2013.
170. Lim B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Elucidating the Change of TRAIL Sensitivity in Basal-Like TNBC Cell Lines by Lapatinib, and Further Therapeutic Implications. Cancer Res 73(24_Suppl), 2013. e-Pub 2013.
171. LIm B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Lapatinib Restores TRAIL-Mediated Apoptosis in TRAIL-resistant TNBC through an off-target strategy-that Appears to be independent of increased Death Receptor expression 73(8_Suppl), 2013. e-Pub 2013.
172. LIm B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Lapatinib Restores TRAIL-Mediated Apoptosis in TRAIL-resistant TNBC through an off-target strategy-that Appears to be independent of increased Death Receptor expression. Cancer Res 73(8_Suppl), 2013. e-Pub 2013.
173. Lim B, Ali SM, Varlotto JM, Higgins K, DeCarmp MM, Recht A, Flickinger JC, Reed M, Toth J, Kelsey CR. Does Anatomic Segmentectomy have Better Outcomes than Wedge Resections in Stage I NSCLC Patients Treated by Sub-Lobar Resection. J Clin Oncol 31(15_Suppl), 2013. e-Pub 2013.
174. Lim B, Ali SM, Varlotto JM, Higgins K, DeCarmp MM, Recht A, Flickinger JC, Reed M, Toth J, Kelsey CR. Does Anatomic Segmentectomy have Better Outcomes than Wedge Resections in Stage I NSCLC Patients Treated by Sub-Lobar Resection 31(15_Suppl), 2013. e-Pub 2013.
175. Rhee SS, Lim B, Kim H, Wang Y, Aziz U, Butt U, Tang W, Vuchak LA, DeMichele A, Troxel AB, Feldman MD, Meinkoth JL, Brose MS. Rap1 GTPase Activating Protein (Rap1GAP) is Down-Regulated in DCIS and Invasive Ductal Carcinoma 71(8_Suppl), 2011. e-Pub 2011.
176. Rhee SS, Lim B, Kim H, Wang Y, Aziz U, Butt U, Tang W, Vuchak LA, DeMichele A, Troxel AB, Feldman MD, Meinkoth JL, Brose MS. Rap1 GTPase Activating Protein (Rap1GAP) is Down-Regulated in DCIS and Invasive Ductal Carcinoma. Cancer Res 71(8_Suppl), 2011. e-Pub 2011.
177. Mintzer DM, Lim B, Pennsylvania Hospital SD, Philadelphia, PA. Breast cancer in the "very elderly": Staging, treatment, and outcomes in patients over age 80 28(15_Suppl), 2010. e-Pub 2010.
178. Mintzer DM, Lim B, Sataloff DM, Hospital P, Philadelphia, PA. Breast cancer in the "very elderly": Staging, treatment, and outcomes in patients over age 80. J Clin Oncol 28(15_Suppl), 2010. e-Pub 2010.
179. Lim B. Abstract CT172: A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes. American Association For Cancer Research.
180. Lim B. Abstract CT277: IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC). American Association For Cancer Research.
181. Lim B. Abstract 452: Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer. American Association For Cancer Research.

Book Chapters

1. Le-Petross, H, Lim, B, Hylton, NM. Role of MR Imaging in Neoadjuvant Therapy Monitoring. 26, 207-220, 2017.
2. Le-Petross CH, Lim B, Hylton N. MRI and Neoadjuvant chemotherapy. In: Breast Oncology: Techniques, Indications, and Interpretation. Springer, 2016.
3. Rizvi SM, Lim B. Current Treatment of Febrile Neutropenia: Tailored, Individual Based Therapy. In: iMOP. Springer International Publishing, 771-8, 2015.
4. Lim B, Hortobagyi. Management of Locally Advanced Breast Cancer, Including Inflammatory Breast Cancer. In: The 4th edition of The MD Anderson Manual of Medical Oncology.
5. Lim B, Hortobagyi. Inflammatory and Locally Advanced Breast Cancer" to Management of Breast Diseases,. In: The UT MDACC, Second Edition.
6. Hobbs, Lim B. Triple negative breast cancer. In: Cancer Medicine, 10th Edition.
7. Lim B, Woodward. Inflammatory Breast Cancer: What to know about this unique, aggressive breast cancer. Cancer Medicine. In: 10th Edition. Chapter on Breast Cancer.

Letters to the Editor

1. Sherry AD, Lim B, Ludmir EB, Msaouel P. Misunderstood trial design: randomisation compels comparison. Lancet Oncol 26: e297, 2025.

Web Publications

1. Lim B. On the Frontline: Breakthroughs in Cancer Research.
2. Lim B. Skip navigation Search Create 9+ Avatar image Novel targeted therapies in breast cancer.
3. Lim B. SABCS 2020 | RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer.
4. Lim B, Peterson L. Inflammatory Breast Cancer: Symptoms, Diagnosis & Management.
5. Lim B. Inflammatory breast cancer survivor finds hope with clinical trial.
6. Lim B. Dr. Bora Lim | Challenging Types of Breast Cancer | SABCS 2022 | Education Session.
7. Lim B. SABCS 2021 | Single-cell genomics and proteogenomics in cancer.
8. Lim B. SABCS 2021 | Highlights at SABCS 2021 for basic science and early-phase clinical trials.
9. Lim B. SABCS 2024 | LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer.
10. Lim B. SABCS 2024 | Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC.
11. Lim B. SABCS 2024 | HIF-2α as an alternate therapeutic target in ER+ breast cancer.
12. Lim B. SABCS 2020 | Novel targeted therapies in breast cancer.
13. Lim B. Dr. Bora Lim and Josh Newby.
14. Lim B. Why you should choose MD Anderson for inflammatory breast cancer treatment.
15. Lim B. Inflammatory breast cancer (IBC) is a rare, aggressive cancer often excluded from clinical trials.
16. Lim B. Meet breast medical oncologist Bora Lim, M.D.
17. Lim B. Unexplored role of HER2 mutant alleles in breast cancer.
18. Lim B. The uncharted role of HER2 mutant alleles in breast cancer.
19. Lim B. Promoting Awareness of Inflammatory Breast Cancer.
20. Lim B. Tumor Transcriptional Activity Predicts Chemotherapy Response in TNBC.
21. Lim B. Dr Lim on the Significance of the FDA Approval of Adjuvant Ribociclib in HR+/HER2– Breast Cancer.
22. Lim B. How These Married Doctors Balance Family and Fighting Rare Cancer Together.
23. Lim B. How to tell when basic science discoveries are ready to translate?.
24. Lim B. Treatment algorithm for TNBC.
25. Lim B. Love and discovery: Houston doctors find love during research at MD Anderson.
26. Lim B. SABCS 2024 Preview: Experts Call Out Key Data to Watch for.
27. Lim B. The uncharted role of HER2 mutant alleles in breast cancer.
28. Lim B. Unexplored Role of HER2 Mutant Alleles in Breast Cancer.